Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Esophageal CancerImmunotherapyInduction TherapyChemoradiotherapySurgery
Interventions
DRUG

Cardonilizumab

Two cycles of Inductive therapy: nab-paclitaxel 250mg/ m2+cisplatin 75mg/ m2+Cardonilizumab 10mg/kg,ivgtt,3 weeks per cycle for 2 cycles

RADIATION

Chemoradiotherapy ±immunotherapy

"Chemoradiotherapy ± immunotherapy:~* PTV: 50-50.4Gy/1.8-2Gy/25-28fractions ②nab-paclitaxel 100mg+cisplatin 25mg/ m2, d1, every 7 days for 3-5 weeks ③Cardonilizumab 10mg/kg,ivgtt,3 weeks per cycle for 2 cycles"

PROCEDURE

Radical surgery

Surgery was evaluated after concurrent chemoradiotherapy according to patients willing and the surgeons' assessment. If patients were accessed with unresectable disease after radiotherapy or refused to receive surgery, Cardonilizumab would be administered for 2 years or until disease progression.

Trial Locations (3)

100021

RECRUITING

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing

Unknown

NOT_YET_RECRUITING

Anyang Cancer Hospital, Anyang

NOT_YET_RECRUITING

The First Affiliated Hospital of Xinxiang Medical University, Xinxiang

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER